Wnt signalling pathway: a new target for the treatment of osteoporosis
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
The prevention and treatment of osteoporosis traditionally involves the use of antiresorptive agents that target osteoclast function. Antiresorptive therapy is not associated with a significant increase in bone mass and, thus, only partially reduces the risk of fractures. For that reason, the search for anabolic agents, which target osteoblast function, represents an urgent medical need. The first approved bone anabolic drug for the treatment of osteoporosis was teriparatide (human parathyroid hormone 1-34). Recently, both human genetics and animal studies have pointed out the role of the Wnt/LRP5 pathway as a major regulator of bone mass accrual. Wnts are secreted glycoproteins that bind to receptor complexes including low-density lipoprotein receptor-related protein (LRP)-5/6 and Frizzled proteins. A subsequent intracellular cascade of events stabilises beta-catenin, leading to its translocation into the nucleus where, associated with Tcf/Lef transcription factors, it triggers gene expression. The existence of many potential pharmacological targets in this pathway makes it attractive for bone anabolic drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Wnt Signaling Pathway in Development and Disease
Logan, C. Y., & Nusse, R. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.010403.113126 · Cited by 5,325
Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation
Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., & Karsenty, G. (1997) · Cell · doi:10.1016/s0092-8674(00)80257-3 · Cited by 4,246
Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z., Deng, J. M., Behringer, R. R., & de Crombrugghe, B. (2002) · Cell · doi:10.1016/s0092-8674(01)00622-5 · Cited by 3,608 · cited 2×
“YU VW, AMBARTSOUMIAN G, VERLINDEN L et al.: FIAT represses ATF4-mediated transcription to regulate bone mass in transgenic mice.”
BackgroundFredriksson, R., Lagerström, M. C., Lundin, L.-G., & Schiöth, H. B. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1256 · Cited by 2,941
Wnt proteins are lipid-modified and can act as stem cell growth factors
Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W., Weissman, I. L., Reya, T., Yates, J. R., & Nusse, R. (2003) · Nature · doi:10.1038/nature01611 · Cited by 2,257
LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development
Gong, Y., Slee, R. B., Fukai, N., Rawadi, G., Roman-Roman, S., Reginato, A. M., Wang, H., Cundy, T., Glorieux, F. H., Lev, D., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00571-2 · Cited by 2,235
Self-citationDay, T. F., Guo, X., Garrett-Beal, L., & Yang, Y. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.03.016 · Cited by 1,616
Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction
Glinka, A., Wu, W., Delius, H., Monaghan, A. P., Blumenstock, C., & Niehrs, C. (1998) · Nature · doi:10.1038/34848 · Cited by 1,608 · cited 1×
“Unlike Sfrps and Wif1, Dickkopf (Dkk) proteins are potent secreted Wnt antagonists that specifically block Wnt/ β-catenin signalling [71].”
BackgroundHigh Bone Density Due to a Mutation in LDL-Receptor–Related Protein 5
Boyden, L. M., Mao, J., Belsky, J., Mitzner, L., Farhi, A., Mitnick, M. A., Wu, D., Insogna, K., & Lifton, R. P. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013444 · Cited by 1,591 · cited 3×
“Targets (2005) 9(5) dominant HBM trait [104,106].”
BackgroundSecreted antagonists of the Wnt signalling pathway
Kawano, Y., & Kypta, R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00623 · Cited by 1,584 · cited 1×
“Today, numerous Sfrps have been described in vertebrates (for review see [69]).”
BackgroundCanonical wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
Glass, D. A., Bialek, P., Ahn, J. D., Starbuck, M., Patel, M. S., Clevers, H., Taketo, M. M., Long, F., McMahon, A. P., Lang, R. A., et al. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.02.017 · Cited by 1,558
Minireview: The OPG/RANKL/RANK System
Khosla, S. (2001) · Endocrinology · doi:10.1210/endo.142.12.8536 · Cited by 1,515 · cited 1×
“Importantly, the two main genes required for osteoclast differentiation, Csf1/M-CSF and TNF-sf11/receptor activator of NF-κB ligand (RANKL), are secreted by the osteoblast [100,101].”
BackgroundSclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366 · cited 1×
“Sost inhibitory activity is mediated through its binding to LRP5/ 6 receptor [89].”
BackgroundVeeman, M. T., Axelrod, J. D., & Moon, R. T. (2003) · Developmental Cell · doi:10.1016/s1534-5807(03)00266-1 · Cited by 1,359 · cited 1×
“Based on the activated intracellular signalling pathway, one can distinguish between the two types of Wnt proteins: β-catenin-dependent Wnts activating the ‘canonical Wnt pathway’ and β-catenin-independent Wnts activating the ‘Wnt/calcium pathway’ [10,11].”
BackgroundLittle, R. D., Folz, C., Manning, S. P., Swain, P. M., Zhao, S.-C., Eustace, B., Lappe, M. M., Spitzer, L., Zweier, S., Braunschweiger, K., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/338450 · Cited by 1,282
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147 · cited 2×
“Finally, Sost is a secreted protein characterised by a cysteine-knot motif and a significant similarity with the dan family of secreted glycoproteins (dan, cerberus/cer1, gremlin/drm, prdc, caronte and dante [84,85]).”
BackgroundKato, M., Patel, M. S., Levasseur, R., Lobov, I., Chang, B. H.-J., Glass, D. A., Hartmann, C., Li, L., Hwang, T.-H., Brayton, C. F., et al. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200201089 · Cited by 1,086 · cited 5×
“The decrease in bone matrix deposition shown by the decreased bone forming rate reported in LRP5-deficient mice [48], and the significant increase of collagens Type I α1 and α2 gene expression when β-catenin is stabilised in differentiated osteoblasts in vivo [130] strongly indicate that Wnt canonical signalling also…”
BackgroundInfluentialKremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling
Mao, B., Wu, W., Davidson, G., Marhold, J., Li, M., Mechler, B. M., Delius, H., Hoppe, D., Stannek, P., Walter, C., et al. (2002) · Nature · doi:10.1038/nature756 · Cited by 1,038
Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011 · cited 2×
“Finally, Sost is a secreted protein characterised by a cysteine-knot motif and a significant similarity with the dan family of secreted glycoproteins (dan, cerberus/cer1, gremlin/drm, prdc, caronte and dante [84,85]).”
BackgroundMao, J., Wang, J., Liu, B., Pan, W., Farr, G. H., Flynn, C., Yuan, H., Takada, S., Kimelman, D., Li, L., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00224-6 · Cited by 839 · cited 6×
“This results in the inhibition of GSK-3β by Frat1 and destabilisation of the Axin/GSK-3β/β-catenin complex, thus preventing the degradation of β-catenin.”
BackgroundInfluentialBoutros, M., Paricio, N., Strutt, D. I., & Mlodzik, M. (1998) · Cell · doi:10.1016/s0092-8674(00)81226-x · Cited by 801 · cited 1×
“Targets (2005) 9(5) 1065 There is a large body of evidence indicating that noncanonical Wnt signalling is also able to activate the c-Jun N-terminal kinase (JNK) pathway [14-18].”
BackgroundNovel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow
Bafico, A., Liu, G., Yaniv, A., Gazit, A., & Aaronson, S. A. (2001) · Nature Cell Biology · doi:10.1038/35083081 · Cited by 772
SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor
Semënov, M., Tamai, K., & He, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504308200 · Cited by 771
A new secreted protein that binds to Wnt proteins and inhibits their activites
Hsieh, J.-C., Kodjabachian, L., Rebbert, M. L., Rattner, A., Smallwood, P. M., Samos, C. H., Nusse, R., Dawid, I. B., & Nathans, J. (1999) · Nature · doi:10.1038/18899 · Cited by 750 · cited 1×
“Targets (2005) 9(5) 1067 Wnt-inhibitory factor 1 (Wif1) is another secreted Wnt antagonist structurally diverse from Sfrps, but also able to antagonise both the canonical and non-canonical Wnt pathways [70].”
BackgroundDrosophila Tcf and Groucho interact to repress Wingless signalling activity
Cavallo, R. A., Cox, R. T., Moline, M. M., Roose, J., Polevoy, G. A., Clevers, H., Peifer, M., & Bejsovec, A. (1998) · Nature · doi:10.1038/26982 · Cited by 730 · cited 1×
“One of these repressors is Groucho, which binds to a specific domain of Tcf (the HMG box) [59], as well as to a variety of different DNA-binding proteins [60].”
BackgroundIdentification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease
Balemans, W., Patel, N., Ebeling, M., Van Hul, E., Wuyts, W., Lacza, C., Dioszegi, M., Dikkers, F. G., Hildering, P., Willems, P. J., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.2.91 · Cited by 698 · cited 12×
“For instance, the Wnt/LRP5 antagonist sclerostin/Sost is selectively expressed by mature osteoblasts and osteocytes.”
BackgroundInfluentialEssential role of β-catenin in postnatal bone acquisition.
Holmen, S. L., Zylstra, C. R., Mukherjee, A., Sigler, R. E., Faugere, M.-C., Bouxsein, M. L., Deng, L., Clemens, T. L., & Williams, B. O. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501900200 · Cited by 584
Van Wesenbeeck, L., Cleiren, E., Gram, J., Beals, R. K., Bénichou, O., Scopelliti, D., Key, L., Renton, T., Bartels, C., Gong, Y., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/368277 · Cited by 568 · cited 1×
“Subsequently, sequence variants in the Lrp5 gene have been significantly associated with differences in BMD and/or fracture risk in several independent epidemiological studies [108-112].”
BackgroundFrzb, a Secreted Protein Expressed in the Spemann Organizer, Binds and Inhibits Wnt-8
Wang, S., Krinks, M., Lin, K., Luyten, F. P., & Moos, M. (1997) · Cell · doi:10.1016/s0092-8674(00)81922-4 · Cited by 518 · cited 7×
“LEYNS L, BOUWMEESTER T, KIM SH, PICCOLO S DE ROBERTIS EM: Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer.”
BackgroundInfluentialMa, Y. L., Cain, R. L., Halladay, D. L., Yang, X., Zeng, Q., Miles, R. R., Chandrasekhar, S., Martin, T. J., & Onyia, J. E. (2001) · Endocrinology · doi:10.1210/endo.142.9.8356 · Cited by 428
Mechanistic insight into osteoclast differentiation in osteoimmunology
Takayanagi, H. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0612-6 · Cited by 413 · cited 1×
“Osteoclast differentiation is controlled by transcription factors such as NF-κB and Nfat-c1 [98,99].”
BackgroundKremen2 modulates Dickkopf2 activity during Wnt/lRP6 signaling
Mao, B., & Niehrs, C. (2003) · Gene · doi:10.1016/s0378-1119(02)01106-x · Cited by 325 · cited 1×
“Interestingly, in the absence of any Wnt ligand, Dkk2 (or a degradation product of Dkk2) may act as a weak agonist of the β-catenin pathway in some cell types [76-78].”
BackgroundWise, a context-dependent activator and inhibitor of Wnt signalling
Itasaki, N., Jones, C. M., Mercurio, S., Rowe, A., Domingos, P. M., Smith, J. C., & Krumlauf, R. (2003) · Development · doi:10.1242/dev.00674 · Cited by 321 · cited 1×
“Wise, another CCN family protein, has been reported to bind LRP5/6 and inhibit Wnt signalling in a cell context-dependent manner [83].”
BackgroundBillin, A. N., Thirlwell, H., & Ayer, D. E. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.18.6882-6890.2000 · Cited by 216
Winkler, D. G., Sutherland, M. S. K., Ojala, E., Turcott, E., Geoghegan, J. C., Shpektor, D., Skonier, J. E., Yu, C., & Latham, J. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m400524200 · Cited by 164
Cited by
Regulation of bone mass by Wnt signaling
Krishnan, V. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28551 · Cited by 1,407
Signaling and transcriptional regulation in osteoblast commitment and differentiation
Huang, W. (2007) · Frontiers in Bioscience · doi:10.2741/2296 · Cited by 649
Zhu, S., Chen, W., Masson, A., & Li, Y.-P. (2024) · Cell Discovery · doi:10.1038/s41421-024-00689-6 · Cited by 463
miR-29 Modulates Wnt Signaling in Human Osteoblasts through a Positive Feedback Loop
Kapinas, K., Kessler, C., Ricks, T., Gronowicz, G., & Delany, A. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.116137 · Cited by 396
Wnt signaling and osteoblastogenesis
Bodine, P. V. N., & Komm, B. S. (2007) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-006-9002-4 · Cited by 285
Metadata
- Authors
- Rawadi, G., & Roman-Roman, S.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2005-09-27
- Volume
- 9
- Issue
- 5
- Pages
- 1063-1077
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2140924177
- Cited by
- 93
- References
- 35
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.